Skip to main content

Advertisement

Table 5 Anthropometric measurements (ITT) at different control times (T1 baseline and, T5, T9, T13) in groups treated with PG and O

From: Randomised, double-blind, clinical investigation to compare orlistat 60 milligram and a customized polyglucosamine, two treatment methods for the management of overweight and obesity

Variable Group T1a T4a T9a T13a
Weight (kg) polyglucosamine 100.6 ± 13.22 97.2 ± 12.37 95.6 ± 12.54 94.3 ± 13.06
orlisat 98.2 ± 11.47 95.5 ± 11.25 94.9 ± 11.99 93.6 ± 11.88
BMI (kg/m2) polyglucosamine 34.6 ± 3.70 33.5 ± 3.62 32.9 ± 3.61 32.5 ± 3.69
orlistat 34.8 ± 4.73 33.8 ± 4.60 33.6 ± 4.69 33.1 ± 4.66
WC (cm) polyglucosamine 112.4 ± 10.95 109.2 ± 11.46 107.4 ± 11.25 105.1 ± 11.21
orlistat 110.0 ± 10.38 107.4 ± 9.98 104.8 ± 9.93 104.1 ± 9.84
  1. aThe differences between groups are not statistically significant (t test)